| 核苷类药物在乙型肝炎后肝硬化治疗中的疗效分析 |
| |
| 引用本文： | 周文兴,吕国良,刘馨. 核苷类药物在乙型肝炎后肝硬化治疗中的疗效分析[J]. 中国生化药物杂志, 2012, 33(2): 170-172 |
| |
| 作者姓名： | 周文兴 吕国良 刘馨 |
| |
| 作者单位： | 辽宁医学院附属第一医院传染科,辽宁锦州,121001 |
| |
| 摘 要： | 目的观察核苷类抗病毒药物拉米夫定(LAM)、阿德福韦酯(ADV)、恩替卡韦(ETV)在失代偿期乙型肝炎肝硬化患者中的疗效。方法失代偿期乙肝后肝硬化患者120名随机分为A、B、C三组,在内科综合治疗的基础上,A组单用LAM(100 mg/d),B组单用ADV(10 mg/d),C组单用ETV(O.5 mg/d)治疗,观察患者3,6,9及12个月时血清生化指标及病毒载量变化。结果经过核苷类似物抗病毒治疗后,各组HBV DNA载量在3,6,9和12个月后均有大幅度下降,ETV组患者HBV DNA载量下降及HBeAg阴转率显著高于LAM组和ADV组。结论 ETV更适合于失代偿期乙肝后肝硬化患者中的抗病毒治疗。
|
| 关 键 词： | 核苷类似物 拉米夫定 阿德福韦酯 恩替卡韦 乙型肝炎病毒 肝硬化 |
Clinical efficacy analysis of nucleoside analogs in the treatment of hepatitis B virus related decompensated cirrhosis |
| |
| ZHOU Wen-xing , LU Guo-liang , LIU Xin. Clinical efficacy analysis of nucleoside analogs in the treatment of hepatitis B virus related decompensated cirrhosis[J]. Chinese Journal of Biochemical Pharmaceutics, 2012, 33(2): 170-172 |
| |
| Authors: | ZHOU Wen-xing LU Guo-liang LIU Xin |
| |
| Affiliation: | (The No.1 Affiliated Hospital of Liaoning Medical University,Jinzhou 121001,China) |
| |
| Abstract: | Purpose To analyze the clinical efficacy of nucleoside analogs:lamivudine(LAM),adefovir dipivoxil(ADV) and entecavir(ETV) in the treatment of decompensated cirrhosis caused by hepatitis B virus.Methods120 patients were randomly divided into 3 groups,including the basic treatment,and the patients in three group were received LAM(100 mg/d),ADV(10 mg/d),ETV(0.5 mg/d),respectively.Serum biochemical parameter and virus load were detected at 3,6,9 and 12 months after the treatment.ResultsCompared with LAM and ADV,ETV presented more facility in inhibiting virus replication.ConclusionETV seemed to be proper for the treatment of patients with hepatitis B virus related decompensated cirrhosis. |
| |
| Keywords: | nucleoside analogs lamivudine adefovir dipivoxil entecavir hepatitis B liver cirrhosis |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
